As regards Directive 2001/20/EC, experience also indicates that the legal form of a Regulation would present advantages for sponsors and investigators, for example in the context of clinical trials taking place in more than one Member State, since they will be able to rely on its provisions directly, but also in the context of safety reporting and labelling of investigational medicinal products. Divergences of approach among different Member States will be therefore kept to a minimum.
Recital 5, Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 20…
In forcesince 16 Apr 2014